Line separator


Innovation for Tuberculosis Vaccine Discovery (ITVD)  (R61/R33 Clinical Trial Not Allowed)

Issued by: National Institute of Allergy and Infectious Diseases (NIAID)

Activity code: R61/R33 Exploratory/Developmental  Phased Award

Funding Opportunity Announcement (FOA) Number: RFA-AI-21-007

Open date (earliest submission): May 30, 2021

Expiration date: July 21, 2021

To support the design of novel tuberculosis (TB) vaccine candidates that exploit innovative approaches and their advancement into preclinical animal model testing. This funding opportunity will use a milestone driven, biphasic award mechanism to fund high risk/exploratory research. Transition to the second phase depends on the successful completion of milestones.

Posted: February 23, 2021

Notice of Special Interest (NOSI): Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design

Issued by: National Institute of Allergy and Infectious Diseases (NIAID)

Release date: September 20, 2020

Expiration date: January 08, 2023

The purpose of this Notice of Special Interest (NOSI) is to stimulate innovative studies to identify and understand the immune responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or progression to active tuberculosis (TB) disease. Studies may focus on any stage of mycobacterial infection or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational TB vaccines and may include HIV-infected or uninfected individuals.

Research supported under this NOSI should go beyond descriptive information currently known about Mtb infection, immune responses to TB vaccines, or immune modulation by non-tuberculous mycobacterial (NTM) infection, or by HIV/AIDS. Applications that include characterization of the timing, anatomical location, and contribution to disease outcome, of mucosal and/or systemic immune responses to mycobacterial infection and/or vaccination are sought. This research is expected to advance understanding of immune mechanisms in Mtb infection/vaccination and contribute to the advancement of new TB vaccines, including in populations also infected with HIV.

Posted: December 17, 2020